The inflammatory spectrum of cardiomyopathies.

"Conflicts of interest TL has no conflicts of interest related to this manuscript, but received educational and research grants from Abbott, Ablative Solutions, Amgen, AstraZeneca, Boehringer-Ingelheim, Daichi Sankyo, Novartis, Sanofi, Servier and Vifor and honoraria from Amgen, Dacadoo, Daichi-Sankyo, Glaxo, Smith & Kline, Firalis, Menarini Foundation, NeuroImmune, Novo Nordisk. BH is inventor on patents that use RNA for diagnosis of myocarditis. Patent protection is in process for MCG for diagnosis and measurement of therapy response in inflammatory cardiomyopathy and for cytokines as targets for therapy in patients with inflammatory cardiomyopathy and in heart failure. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The Reviewer DP declared a past co-authorship with the authors BH, TL, and PS."

"This work was supported by National Institutes of Health (NIH) R01 HL164520, R21 AI145356, R21 AI152318, R21 AI154927 to DF; American Heart Association 20TPA35490415 to DF; NIH grants TL1 TR002380 to DF; the For Elyse Foundation to DF; and Mayo Clinic Center for Regenerative Medicine to DF.PM is supported by MCIN-ISCIII-Fondo de Investigación Sanitaria (PI22/01759), (PMPTA22/00090-BIOCARDIOTOX) and Comunidad de Madrid (P2022/BMD-7209-INTEGRAMUNE-CM)."